DaVita Fresenius Lawsuit: Washington Says Doctor Noncompetes Lock In Dialysis Monopolies
Washington sued DaVita and Fresenius over noncompetes for dialysis medical directors across 80 centres. What the case alleges and what could change.
DaVita Fresenius Lawsuit: Washington Says Doctor Noncompetes Lock In Dialysis Monopolies
Washington sued DaVita and Fresenius over noncompetes for dialysis medical directors across 80 centres. What the case alleges and what could change.
Hims & Hers FTC Lawsuit Widens as Five More States Join Health Data Case
Arizona, Florida, Nebraska, Ohio and Wisconsin joined the FTC suit accusing Hims & Hers of sharing health data with Meta and Snap and making plans hard to cancel.
Pfizer Blackstone Deal: $1.5B Bet on a Monthly Obesity Shot, Explained
Blackstone will fund up to $1.5B of Pfizer berobenatide development through 2028, repaid only if the monthly GLP-1 wins US approval. How the deal works.
WHO Food Profiling Model Targets Added Colours, Flavours and Sweeteners
WHO draft would flag packaged foods with added colours, flavours or sweeteners for labels, marketing limits or taxes. How it works, industry pushback and the Nov 27 deadline.
IMVIONIX Beovu Acquisition: Ex-Alimera Team Takes Over Novartis Eye Drug
IMVIONIX has acquired US and Canadian rights to Novartis eye drug Beovu. Who the buyers are, Beovu trial data and safety history, and what to watch.
CVS Split Explained: Aetna and Caremark Stay Together as 9,000 Stores Become CVS Pharmacy
CVS Health will separate into a healthcare solutions company and a standalone CVS Pharmacy by the first half of 2028. Who gets what, the Q3 numbers behind the move and what it means for patients and drugmakers.
Compounding API Warning Letters: FDA Targets Chinese Makers That Refused Records
The FDA has issued warning letters to two Chinese API makers that shipped ingredients for US compounding and refused records requests. What the letters say and why it matters.
GLOBE Model Lawsuit: BIO Joins Fight to Stop Medicare International Drug Pricing
BIO and two California biotech groups have sued to block Medicare’s GLOBE model, which ties Part B drug rebates to prices in 19 countries from 2027.
COMP360 Psilocybin NDA Filed: What Compass Needs for a 2027 Launch
Compass Pathways has completed its COMP360 psilocybin NDA for treatment-resistant depression. Here is the Phase 3 data, the voucher timeline and the DEA hurdle.
